GMT

Citizens Financial Group to Participate at the Barclays Americas Select Franchise Conference

Retrieved on: 
Lunedì, Aprile 29, 2024
Banking, Professional Services, Citizens Financial Group, GMT, CFG, Conference

Citizens Financial Group, Inc. (NYSE: CFG) announced today that Chairman and CEO Bruce Van Saun will participate at the Barclays Americas Select Franchise Conference to be held on Wednesday, May 8, 2024 at 10:45 am GMT.

Key Points: 
  • Citizens Financial Group, Inc. (NYSE: CFG) announced today that Chairman and CEO Bruce Van Saun will participate at the Barclays Americas Select Franchise Conference to be held on Wednesday, May 8, 2024 at 10:45 am GMT.
  • The live webcast will be available at https://investor.citizensbank.com under Events & Presentations.

Leading "move-and-earn" app STEPN partners with adidas on exclusive NFT sneakers

Retrieved on: 
Lunedì, Aprile 15, 2024
Sale, Adidas, Blockchain, Partnership, Collection, Non-fungible token, Animation, FSL, GMT, NFT, Shell, Cryptocurrency

SYDNEY, April 15, 2024 /PRNewswire/ -- Move-and-earn lifestyle app STEPN today announces the launch of STEPN x adidas Genesis Sneakers – a limited-edition NFT collection developed in collaboration with adidas.

Key Points: 
  • SYDNEY, April 15, 2024 /PRNewswire/ -- Move-and-earn lifestyle app STEPN today announces the launch of STEPN x adidas Genesis Sneakers – a limited-edition NFT collection developed in collaboration with adidas.
  • The STEPN x adidas Genesis Sneakers collection drops on Wednesday, April 17, on STEPN's sister NFT marketplace MOOAR .
  • This genesis collection is the first of a series of co-branded activities between STEPN and adidas over a one-year partnership that will see further NFT drops and physical, wearable items on the roadmap.
  • The STEPN x adidas Genesis Sneakers collection will be sold via the MOOAR marketplace and priced in STEPN's native GMT token, at 10,000 GMT each.

Leading "move-and-earn" app STEPN partners with adidas on exclusive NFT sneakers

Retrieved on: 
Lunedì, Aprile 15, 2024
Sale, Adidas, Blockchain, Partnership, Collection, Non-fungible token, Animation, FSL, GMT, NFT, Shell, Cryptocurrency

SYDNEY, April 15, 2024 /PRNewswire/ -- Move-and-earn lifestyle app STEPN today announces the launch of STEPN x adidas Genesis Sneakers – a limited-edition NFT collection developed in collaboration with adidas.

Key Points: 
  • SYDNEY, April 15, 2024 /PRNewswire/ -- Move-and-earn lifestyle app STEPN today announces the launch of STEPN x adidas Genesis Sneakers – a limited-edition NFT collection developed in collaboration with adidas.
  • The STEPN x adidas Genesis Sneakers collection drops on Wednesday, April 17, on STEPN's sister NFT marketplace MOOAR .
  • This genesis collection is the first of a series of co-branded activities between STEPN and adidas over a one-year partnership that will see further NFT drops and physical, wearable items on the roadmap.
  • The STEPN x adidas Genesis Sneakers collection will be sold via the MOOAR marketplace and priced in STEPN's native GMT token, at 10,000 GMT each.

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mercoledì, Aprile 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Retrieved on: 
Mercoledì, Aprile 3, 2024
Webcast, Patient, GMT, EDT

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.

Key Points: 
  • REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.
  • Anil Okay, Chief Commercial Officer, will be providing the update.
  • Information on how to access the webcast is posted on Alvotech’s investor website at https://investors.alvotech.com/events/event-details/market-update-2024-0... .
  • The webcast will be archived and available for replay for 90 days after the event.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Giovedì, Marzo 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Giovedì, Marzo 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
Mercoledì, Marzo 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

Iveco Group announces its Capital Markets Day to be held 14th March 202

Retrieved on: 
Martedì, Marzo 12, 2024
EXM, EST, ASTRA, Q&A, Iveco, Agriculture, IDV, FPT Industrial, IVG, IVECO, GMT

Iveco Group N.V. (EXM: IVG) announced today that there will be an Iveco Group Capital Markets Day on Thursday, 14th March 2024.

Key Points: 
  • Iveco Group N.V. (EXM: IVG) announced today that there will be an Iveco Group Capital Markets Day on Thursday, 14th March 2024.
  • A live streaming of the Iveco Group Capital Markets Day will begin at 1:30 p.m. CET / 12:30 p.m. GMT / 8:30 a.m. EST on Thursday, 14th March 2024.
  • Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society.
  • Iveco Group employs more than 35,000 people around the world and has 20 industrial sites and 29 R&D centres.

OCP Announces Date of Fourth Quarter and Full Year 2023 Earnings

Retrieved on: 
Giovedì, Marzo 21, 2024
Agriculture, Natural Resources, Other Natural Resources, EST, OCP, GMT, Security (finance)

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2024 results on Thursday, March 28, 2024.

Key Points: 
  • OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2024 results on Thursday, March 28, 2024.
  • The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers on the OCP Intralinks portal from 10:00 a.m. EST, 2:00 p.m. Morocco and London time (GMT).
  • OCP senior management will host a conference call to discuss fourth quarter and full year 2023 results at 11:00 a.m. EST, 3:00 p.m. Morocco and London time (GMT), on Thursday, March 28, 2024, for holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers.